Literature DB >> 10224041

Domain structure of pleiotrophin required for transformation.

N Zhang1, R Zhong, T F Deuel.   

Abstract

The pleiotrophin (PTN) gene (Ptn) is a potent proto-oncogene that is highly expressed in many primary human tumors and constitutively expressed in cell lines derived from these tumors. The product of the Ptn gene is a secreted 136-amino acid heparin binding cytokine with distinct lysine-rich clusters within both the N- and C-terminal domains. To seek domains of PTN functionally important in neoplastic transformation, we constructed a series of mutants and tested their transforming potential by four independent criteria. Our data establish that a domain within PTN residues 41 to 64 and either but not both the N- or C-terminal domains are required for transformation; deletion of both the N and C termini abolishes the transformation potential of PTN. Furthermore, deletion of two internal 5-amino acid residue repeats enhances the transformation potency of PTN 2-fold. Our data indicate that PTN residues 41-64 contain an essential domain for transformation and suggest the hypothesis that this domain requires an additional interaction of the highly basic clusters of the N or C terminus of PTN with a negatively charged "docking" site to enable the transforming domain itself to engage and initiate PTN signaling through its cognate receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10224041     DOI: 10.1074/jbc.274.19.12959

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Pleiotrophin regulates serine phosphorylation and the cellular distribution of beta-adducin through activation of protein kinase C.

Authors:  Harold Pariser; Gonzalo Herradon; Laura Ezquerra; Pablo Perez-Pinera; Thomas F Deuel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

2.  A Pleiotrophin C-terminus peptide induces anti-cancer effects through RPTPβ/ζ.

Authors:  Zoi Diamantopoulou; Oya Bermek; Apostolos Polykratis; Yamina Hamma-Kourbali; Jean Delbé; José Courty; Panagiotis Katsoris
Journal:  Mol Cancer       Date:  2010-08-25       Impact factor: 27.401

Review 3.  Pleiotrophin and peripheral nerve injury.

Authors:  Li Jin; Chen Jianghai; Liu Juan; Kang Hao
Journal:  Neurosurg Rev       Date:  2009-05-08       Impact factor: 3.042

4.  Pleiotrophin antagonizes Brd2 during neuronal differentiation.

Authors:  Pablo Garcia-Gutierrez; Francisco Juarez-Vicente; Debra J Wolgemuth; Mario Garcia-Dominguez
Journal:  J Cell Sci       Date:  2014-04-02       Impact factor: 5.285

5.  Pleiotrophin enhances PDGFB-induced gliomagenesis through increased proliferation of neural progenitor cells.

Authors:  Lei Zhang; Liisi Laaniste; Yiwen Jiang; Irina Alafuzoff; Lene Uhrbom; Anna Dimberg
Journal:  Oncotarget       Date:  2016-12-06

6.  Pleiotrophin gene therapy for peripheral ischemia: evaluation of full-length and truncated gene variants.

Authors:  Qizhi Fang; Pamela Y Mok; Anila E Thomas; Daniel J Haddad; Shereen A Saini; Brian T Clifford; Neel K Kapasi; Olivia M Danforth; Minako Usui; Weisheng Ye; Emmy Luu; Rikki Sharma; Maya J Bartel; Jeremy A Pathmanabhan; Andrew A S Ang; Richard E Sievers; Randall J Lee; Matthew L Springer
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.